Literature DB >> 18815451

Evaluation of the impact of memantine treatment initiation on psychotropics use: a study from the French national health care database.

Jean-Sébastien Vidal1, Jean-Marc Lacombe, Jean-François Dartigues, Florence Pasquier, Philippe Robert, Christophe Tzourio, Annick Alpérovitch.   

Abstract

BACKGROUND: Clinical studies reported that treatments for Alzheimer's disease may have an impact on behavioral and psychiatric disorders. We tested the hypothesis that memantine treatment initiation modifies psychotropic medication in real-life practice patients.
METHODS: A 2-year follow-up cohort study was performed. A sample of patients treated in the general population, extracted from the database of the French national healthcare system (CNAM-TS), was examined. The sample included 4,600 memantine-treated patients (mean age 79.8 years, 69% women) randomly selected from the database of the CNAM-TS covering 69% of the French population aged 65 years and over. The follow-up rate was 95.0%. This database includes exhaustive data on drug consumption. We used interrupted time series analysis of the proportion of psychotropics users (all psychotropic drugs and specific categories) before and after onset of memantine.
RESULTS: There was a 39-50% regular increase in patients treated with psychotropic drugs before memantine initiation This increasing trend stopped after memantine initiation, the proportion of psychotropic users remaining stable around 53% up to the end. The trends before and after memantine onset were significantly different (p < 0.001).
CONCLUSIONS: Our results suggest a temporal relationship between the onset of memantine and the stabilization of psychotropic drugs use in this large sample of elderly patients. 2008 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18815451     DOI: 10.1159/000158226

Source DB:  PubMed          Journal:  Neuroepidemiology        ISSN: 0251-5350            Impact factor:   3.282


  11 in total

1.  Behavioral disturbance in dementia.

Authors:  Abhilash K Desai; Lori Schwartz; George T Grossberg
Journal:  Curr Psychiatry Rep       Date:  2012-08       Impact factor: 5.285

2.  Trends in Drug Prescription Rates for Dementia: An Observational Population-Based Study in France, 2006-2014.

Authors:  Mathilde François; Jonathan Sicsic; Alexis Elbaz; Nathalie Pelletier Fleury
Journal:  Drugs Aging       Date:  2017-09       Impact factor: 3.923

3.  Duration of new antidepressant use and factors associated with discontinuation among community-dwelling persons with Alzheimer's disease.

Authors:  Reetta Kettunen; Heidi Taipale; Anna-Maija Tolppanen; Antti Tanskanen; Jari Tiihonen; Sirpa Hartikainen; Marjaana Koponen
Journal:  Eur J Clin Pharmacol       Date:  2018-11-09       Impact factor: 2.953

Review 4.  Memantine: New prospective in bipolar disorder treatment.

Authors:  Giulia Serra; Francesca Demontis; Francesca Serra; Lavinia De Chiara; Andrea Spoto; Paolo Girardi; Giulio Vidotto; Gino Serra
Journal:  World J Psychiatry       Date:  2014-12-22

Review 5.  Once-daily memantine: a guide to its use in moderate to severe Alzheimer's disease in the EU.

Authors:  Katherine A Lyseng-Williamson; Kate McKeage
Journal:  Drugs Aging       Date:  2013-01       Impact factor: 3.923

6.  Update on the use of memantine in Alzheimer's disease.

Authors:  Robert J van Marum
Journal:  Neuropsychiatr Dis Treat       Date:  2009-05-20       Impact factor: 2.570

Review 7.  Memantine: a review of its use in moderate to severe Alzheimer's disease.

Authors:  Kate McKeage
Journal:  CNS Drugs       Date:  2009-10       Impact factor: 5.749

Review 8.  Management of agitation and aggression associated with Alzheimer disease.

Authors:  Clive G Ballard; Serge Gauthier; Jeffrey L Cummings; Henry Brodaty; George T Grossberg; Philippe Robert; Constantine G Lyketsos
Journal:  Nat Rev Neurol       Date:  2009-05       Impact factor: 42.937

9.  Trends in the prevalence of antipsychotic drug use among patients with Alzheimer's disease and other dementias including those treated with antidementia drugs in the community in the UK: a cohort study.

Authors:  Carlos Martinez; Roy W Jones; Stephan Rietbrock
Journal:  BMJ Open       Date:  2013-01-07       Impact factor: 2.692

10.  Critical appraisal of the long-term impact of memantine in treatment of moderate to severe Alzheimer's disease.

Authors:  Umamon Puangthong; Ging-Yuek Robin Hsiung
Journal:  Neuropsychiatr Dis Treat       Date:  2009-11-02       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.